A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease | Zendy

Annamaria Colao | Zendy; Stephan Petersenn | Zendy; John NewellPrice | Zendy; James W. Findling | Zendy; Feng Gu | Zendy; Mario Maldonado | Zendy; U Schoenherr | Zendy; Dipl.-Biol. | Zendy; David Mills | Zendy; Luiz Roberto Salgado | Zendy; Beverly M.K. Biller | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

Author(s) -

Annamaria Colao,

Stephan Petersenn,

John NewellPrice,

James W. Findling,

Feng Gu,

Mario Maldonado,

U Schoenherr,

Dipl.-Biol.,

David Mills,

Luiz Roberto Salgado,

Beverly M.K. Biller

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1105743

Subject(s) - medicine , pasireotide , cushing's disease , urinary system , somatostatin , gastroenterology , endocrinology , somatostatin receptor , cushing syndrome , octreotide , urology , disease , acromegaly , hormone , growth hormone

Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research